Neuberger Berman Group
SLNO

Neuberger Berman Group’s Soleno Therapeutics SLNO Stock Holding History

Neuberger Berman Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54,939
Closed -$4.6M – 2140
2025
Q2 		$4.6M Buy
+54,939
New +$4.11M ﹤0.01% 984

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Neuberger Berman Group's SLNO Position: Q3 2025 in Review

Neuberger Berman Group sold out of Soleno Therapeutics (SLNO) in Q3 2025, closing a stake of 54,939 shares — an estimated $4.6M sold.

Neuberger Berman Group first reported a position in SLNO in Q2 2025 and held it in 1 quarter. The position peaked at $4.6M in Q2 2025. 240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • Neuberger Berman Group reported no remaining Soleno Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Neuberger Berman Group sold 54,939 Soleno Therapeutics shares in Q3 2025, an estimated $4.6M.
  • Neuberger Berman Group first reported a position in Soleno Therapeutics in Q2 2025 and held it in 1 quarter.
  • Neuberger Berman Group's Soleno Therapeutics position peaked at $4.6M in Q2 2025.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on Neuberger Berman Group's 13F filing for Q3 2025, filed 12 Nov 2025.